Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001415889-25-001557
Filing Date
2025-01-16
Accepted
2025-01-16 16:44:32
Documents
2
Period of Report
2025-01-06

Document Format Files

Seq Description Document Type Size
1 form3-01162025_090127.html 3  
1 form3-01162025_090127.xml 3 3219
2 ex24-01162025_090130.htm EX-24 6961
  Complete submission text file 0001415889-25-001557.txt   11638
Mailing Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169
Business Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169 212-847-9841
Y-mAbs Therapeutics, Inc. (Issuer) CIK: 0001722964 (see all company filings)

IRS No.: 474619612 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O Y-MABS THERAPEUTICS, INC. 230 PARK AVENUE, SUITE 3350 NEW YORK NY 10169
Business Address
LaRocca John (Reporting) CIK: 0001732197 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-38650 | Film No.: 25536162